Financials
Financial year 2025
Worth noting
- A loss two years in a row.
- Little cash and receivables against the short-term debts.
- Figures corrected afterwards (2023).
Gross margin
€ 1.3 million
▲ 27% vs 2024
Profit
Caution€ -444,073
▲ 51% vs 2024
Debts
Low€ 6.9 million
▼ 24% vs 2024
AQUILON PHARMACEUTICALS from Seraing, company number BE0540870218, closed financial year 2025 with a result of € -444,073 after tax. For that financial year AQUILON PHARMACEUTICALS recorded a gross margin of € 1.3 million and equity of € 4.3 million. Compared with financial year 2024, the result moved from € -913,660 to € -444,073. The company made a loss. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 22, 2026.
What happened at AQUILON PHARMACEUTICALS?
What happened at AQUILON PHARMACEUTICALS in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Charles NELLES stepped down as director. NBB
- Didier CATALDO stepped down as director. NBB
- Frank PIETERS stepped down as director. NBB
- MAES PHARMCONSULT SRL stepped down as director. NBB
- SCALE 1 SA stepped down as director. NBB
- New annual accounts for financial year 2025: loss of € 444,073. Source: NBB ↗
- Charles NELLES became a director. NBB
- Didier CATALDO became a director. NBB
In short
From € 629,068 loss in 2021 to € 444,073 loss in 2025.
On average € 144,500 of value added per employee in 2025.
A new publication or filing at AQUILON PHARMACEUTICALS? We notify you, reason included.
Follow AQUILON PHARMACEUTICALSNeed more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
Behind AQUILON PHARMACEUTICALS are Moshe MANOR and Hassan BENAMEUR.
Directors
According to the 2025 annual accounts
Moshe MANOR
Director
since 2023
Hassan BENAMEUR
Director
since 2023
Didier CATALDO
Director
since 2024 · until 2030
Charles NELLES
Director
since 2025 · until 2031
Frank PIETERS
Director
since 2024 · until 2030
since 2024 · until 2030
Director · represented by Gauthier VAN DER ELST
since 2024 · until 2030
Establishments
Establishment units
Physical locations of this company
Rue du Bois St-Jean 15/1
4102 Seraing
Rue Porte de Lorette(VIS) 76
4600 Visé
Active since 16 October 2013
Quai de la Boverie 59 box 2
4020 Liège
Active since 1 June 2019
Rue Auguste Piccard 48
6041 Charleroi
Active since 1 June 2019
Rue du Bois St-Jean 15 box 1
4102 Seraing
Active since 16 July 2021
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 6 companies are registered at this address.
SYNGULON
€ 142,835 gross margin · 2023
ARTESIA ENVIRONNEMENT
€ 1 million gross margin · 2025
ALPHACOMSOLUTION
€ 558,735 gross margin · 2025
Société internationale pour l'étude de l'adhésion médicamenteuse
ALIZES PHARMA
+1 more
Website
Technologies
Hosting & Email
Email provider
Microsoft 365
Hosting
MICROSOFT-CORP-MSN-AS-BLOCK - Microsoft Corporation, US
Domain
Domain
aquilonpharma.com
Registered
2013-12-31
Registrar
OVH sas
Expires
2026-12-31
Website info
Features
Security
Details
- Company number
- 0540.870.218
- VAT number
- BE 0540.870.218
- Registered office
- Rue du Bois St-Jean 15/1, 4102 Seraing
- Names & denominations
- AQUILON PHARMACEUTICALS
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 16 October 2013
- Peppol
- Active · Active since 6 Nov 2025
- Activities · NACE
Speur- en ontwikkelingswerk op biotechnologisch gebied
Activiteiten op het gebied van voeding
Overige menselijke gezondheidszorg, n.e.g.